The concept of Antibody-Drug Conjugates (ADCs) as simple "chemo attached to an antibody" is a significant oversimplification. True efficacy is highly dependent on complex factors like the linker's cleavage properties within the acidic tumor microenvironment, creating a "bystander effect" that is crucial to their function.

Antibody-drug conjugates (ADCs) can cause immunogenic cell death, remodeling the tumor microenvironment and enhancing antigen presentation. This mechanism could potentially make PD-L1 negative ('cold') tumors responsive to immune checkpoint inhibitors, creating a strong rationale for investigating ADC-immunotherapy combinations in this patient population.

Modern antibody-drug conjugates (ADCs) like trastuzumab deruxtecan can kill nearby cancer cells that don't express the target protein. This 'bystander effect' is a game-changer, allowing ADCs to be effective even in tumors with varied (heterogeneous) protein expression, which has historically been a major clinical challenge.

A defining characteristic of antibody-drug conjugates is not just their response rate, but their remarkable duration of response. Patients who respond often maintain that response for a significantly longer period than with standard chemotherapy, a benefit likely attributable to the ADC's effect on the tumor microenvironment.

A simple and effective way to explain antibody-drug conjugates (ADCs) to patients is the 'package of mail' analogy. The antibody is the address label directing the therapy to the cancer cell (the house), and the chemotherapy 'payload' is the package itself, which is delivered and opened inside to kill the cell.

To mitigate the severe toxicity of promising pan-RAS inhibitors, companies are adopting antibody-drug conjugate (ADC) technology. This marks a strategic expansion for ADCs, moving beyond traditional cytotoxic chemotherapy payloads to delivering highly specific targeted therapies, aiming to improve the therapeutic window of potent new drug classes.

A new wave of antibody-drug conjugates (ADCs) is transforming ovarian cancer treatment. These 'heat-seeking missiles' deliver potent chemotherapy payloads directly to tumor cells, achieving response rates from 23% to over 60% in biomarker-selected populations. This far surpasses the efficacy of conventional chemotherapy in resistant settings.

Antibody-drug conjugates can disrupt the tumor microenvironment, leading to an influx of immune cells. This may turn an immunologically "cold" tumor "hot," creating a rationale for re-challenging with an immune checkpoint inhibitor, even if the patient's tumor previously did not respond to one.

Unlike older antibody-drug conjugates (ADCs), newer agents are designed so their chemotherapy payload can diffuse out of the target cell and kill nearby tumor cells that may not even express the target antigen. This "bystander effect" significantly enhances their anti-tumor activity.